Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

LL-37 cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established LL-37 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. The first-in-man venous leg ulcer trial treated for 4 weeks after a 3-week placebo run-in, with 4 weeks of follow-up 9.
  2. The phase IIb trial comprised a 3-week open-label run-in on placebo, a 13-week randomized double-blind treatment period and a 4-month (16-week) observation period; patients whose target wound closed attended four post-closure visits 1.
  3. The diabetic foot ulcer trial treated participants for 4 consecutive weeks, with no participant withdrawing during that period 10.
  4. The melanoma registry record describes treatment for up to 8 weeks, with photography at 4 and 8 weeks 11.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • LL-37 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established LL-37 cycle length?
No. Human studies administered LL-37 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of LL-37?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
LL-37 dosing reference Full research page

References

  1. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial Wound Repair and Regeneration. 2021
  2. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity Pharmacological Reports. 2016
  3. Cathelicidins: Immunomodulatory Antimicrobials Vaccines. 2018
  4. Cathelicidins: a family of endogenous antimicrobial peptides Current Opinion in Hematology. 2002
  5. LL-37 (CID 16198951) — computed properties PubChem. 2026
  6. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  7. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) FDA. 2026
  8. Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Wound Healing (NCT04098562) ClinicalTrials.gov. 2019
  9. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial Wound Repair Regen. 2014
  10. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial (registry record NCT04098562) Arch Dermatol Res. 2023
  11. Intratumoral Injections of LL37 for Melanoma (NCT02225366), completed phase 1/2 registry record with posted results ClinicalTrials.gov. 2020
  12. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features J Cutan Pathol. 2018